Description:Cystic fibrosis (CF) is characterized by severe metabolic and lipid dysregulation driven by chronic inflammation, oxidative stress, and CFTR dysfunction. The primary aim of this study is to assess the biochemical effects of three CFTR modulator therapies Trikafta® elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta®), Symdeko® tezacaftor/ivacaftor (TI; Symdeko®), and Orkambi® lumacaftor/ivacaftor (LI; Orkambi®) in plasma samples from CF patients through untargeted metabolomic and lipidomic analyses.